London, 27 October 2014, 12:30 GMT: Norgine B.V. today announced that it has expanded the licensing agreement with PlasmaTech Biopharmaceuticals for MUGARD®, a medical device for the prevention and management of the lesions and symptoms of oral mucositis, to now include Australia and New Zealand.
Under the terms of the agreement, Norgine will assume full responsibility for MUGARD®’s development, manufacturing, registration, distribution and commercialisation in Australia and New Zealand.
Norgine entered into a license agreement with PlasmaTech Biopharmaceuticals, formerly known as Access Pharmaceuticals Inc, to develop and commercialise MUGARD® in Europe on 7 August 2014.
Peter Stein, CEO at Norgine said: “This extended partnership with PlasmaTech Biopharmaceuticals provides an excellent opportunity to ensure that cancer patients affected by oral mucositis can access MUGARD® in some territories of the South Pacific region. This collaboration is further evidence of Norgine’s commitment to acquire speciality pharmaceutical products to strengthen its portfolio.”
Commenting on the news, Scott Schorer, CEO of PlasmaTech Biopharmaceuticals. stated, “PlasmaTech Biopharmaceuticals is pleased to announce this additional partnership with Norgine, a European specialist pharmaceutical company, as it further validates our global MUGARD® commercial strategy”. He added: “With product offerings in complementary therapeutic areas and an established presence in the cancer supportive care space, Norgine is an ideal partner for us. This partnership will help to drive commercial adoption in Australia and New Zeland and facilitate access of a proven treatment option to help protect patients from oral mucositis, a debilitating side effect.”
Ends
NOTES TO EDITORS
Media:
Charlotte Andrews: Tel: +44 (0)1895 453669, Mob: +44 (0)7714 061485
Peter Martin: Tel: +44 (0)1895 453744, Mob: +44 (0)7799 078744
Follow us @norgine
About MUGARD®
MUGARD® Muco-Adhesive Oral Rinse is a non-sterile slightly viscous liquid, formulated to adhere to the mucosal surface of the mouth, for the prevention and treatment of oral mucositis.
About Norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2013, Norgine’s total revenue was €274 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
About PlasmaTech Biopharmaceuticals
Formerly Access Pharmaceuticals, Inc., PlasmaTech Biopharmaceutcials, Inc. is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, Salt Diafiltration Process (SDF™) and Polymer Hydrogel Technology (PHT™), PlasmaTech Bio is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ and multiple follow-on products in development. For more information visit, www.plasmatechbio.com.
MUGARD is a registered trademark of Access Pharmaceuticals, Inc., licensed to the Norgine group of companies.